These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 18365201)
21. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Gacche RN; Meshram RJ Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944 [TBL] [Abstract][Full Text] [Related]
22. Flow-correlated dilution of a regular network leads to a percolating network during tumor-induced angiogenesis. Paul R Eur Phys J E Soft Matter; 2009 Sep; 30(1):101-14. PubMed ID: 19777279 [TBL] [Abstract][Full Text] [Related]
23. Mathematical modeling of capillary formation and development in tumor angiogenesis: penetration into the stroma. Levine HA; Pamuk S; Sleeman BD; Nilsen-Hamilton M Bull Math Biol; 2001 Sep; 63(5):801-63. PubMed ID: 11565406 [TBL] [Abstract][Full Text] [Related]
24. Continuous and discrete mathematical models of tumor-induced angiogenesis. Anderson AR; Chaplain MA Bull Math Biol; 1998 Sep; 60(5):857-99. PubMed ID: 9739618 [TBL] [Abstract][Full Text] [Related]
25. In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Goodwin AM Microvasc Res; 2007; 74(2-3):172-83. PubMed ID: 17631914 [TBL] [Abstract][Full Text] [Related]
26. Normalization of Snai1-mediated vessel dysfunction increases drug response in cancer. Hoffmann H; Wartenberg M; Vorlova S; Karl-Schöller F; Kallius M; Reinhardt O; Öztürk A; Schuhmair LS; Burkhardt V; Gätzner S; Scheld D; Nandigama R; Zernecke A; Herterich S; Ergün S; Rosenwald A; Henke E Oncogene; 2024 Aug; 43(35):2661-2676. PubMed ID: 39095583 [TBL] [Abstract][Full Text] [Related]
27. Written in the blood. Lewis R Nature; 2006 Mar; 440(7084):710-1. PubMed ID: 16637100 [No Abstract] [Full Text] [Related]
28. Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies. Maes H; Olmeda D; Soengas MS; Agostinis P FEBS J; 2016 Jan; 283(1):25-38. PubMed ID: 26443003 [TBL] [Abstract][Full Text] [Related]
29. Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs. Gevertz JL Adv Exp Med Biol; 2016; 936():191-208. PubMed ID: 27739049 [TBL] [Abstract][Full Text] [Related]
30. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. Lopes-Coelho F; Martins F; Pereira SA; Serpa J Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438 [TBL] [Abstract][Full Text] [Related]
31. Evolutionary emergence of angiogenesis in avascular tumors using a spatial public goods game. Salimi Sartakhti J; Manshaei MH; Basanta D; Sadeghi M PLoS One; 2017; 12(4):e0175063. PubMed ID: 28399181 [TBL] [Abstract][Full Text] [Related]
32. [Investigation of the Influence of Angiogenesis on Tumor Growth with the Use of a Mathematical Model]. Kolobov AV; Kuznetsov MB Biofizika; 2015; 60(3):555-63. PubMed ID: 26349221 [TBL] [Abstract][Full Text] [Related]
33. A therapy inactivating the tumor angiogenic factors. Morales-Rodrigo C Math Biosci Eng; 2013 Feb; 10(1):185-98. PubMed ID: 23311368 [TBL] [Abstract][Full Text] [Related]
34. Tie-1: A potential target for anti-angiogenesis therapy. Yang P; Chen N; Jia JH; Gao XJ; Li SH; Cai J; Wang Z J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):615-622. PubMed ID: 26489611 [TBL] [Abstract][Full Text] [Related]
35. Tumor angiogenesis and vascular patterning: a mathematical model. Travasso RD; Corvera Poiré E; Castro M; Rodríguez-Manzaneque JC; Hernández-Machado A PLoS One; 2011; 6(5):e19989. PubMed ID: 21637756 [TBL] [Abstract][Full Text] [Related]
36. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Bikfalvi A; Bicknell R Trends Pharmacol Sci; 2002 Dec; 23(12):576-82. PubMed ID: 12457776 [TBL] [Abstract][Full Text] [Related]
37. The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic. Ye W Dev Cell; 2016 Apr; 37(2):114-25. PubMed ID: 27093081 [TBL] [Abstract][Full Text] [Related]
38. Vessel co-option and resistance to anti-angiogenic therapy. Kuczynski EA; Reynolds AR Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479 [TBL] [Abstract][Full Text] [Related]
39. Vascular disrupting agents in cancer therapy. Smolarczyk R; Czapla J; Jarosz-Biej M; Czerwinski K; Cichoń T Eur J Pharmacol; 2021 Jan; 891():173692. PubMed ID: 33130277 [TBL] [Abstract][Full Text] [Related]
40. Computational modelling suggests complex interactions between interstitial flow and tumour angiogenesis. Vilanova G; Burés M; Colominas I; Gomez H J R Soc Interface; 2018 Sep; 15(146):. PubMed ID: 30185542 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]